Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)
Impact of Different Treatment Modalities on Immunity Against COVID-19
Sponsor: Beni-Suef University
Listed as NCT04553705, this PHASE2/PHASE3 trial focuses on Covid19 and Immunodeficiency and remains completed. Sponsored by Beni-Suef University, it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Completed PHASE2/PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
▶ Show 4 earlier versions
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beni-Suef University
- Maternity and Children Hospital, Makkah
- University of Arizona
For direct contact, visit the study record on ClinicalTrials.gov .